Novo Integrated Sciences, Inc.
NVOS · OTC
8/31/2024 | 8/31/2023 | 8/31/2022 | 8/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 5.7% | 7.1% | 26.1% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 43.2% | 39.4% | 40.9% | 41.1% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -75.8% | -46.5% | -191.5% | -27.7% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -121.3% | -105.1% | -279.9% | -48% |
| EPS Diluted | -0.9 | -1.3 | -11.28 | -1.8 |
| % Growth | 30.8% | 88.5% | -526.7% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |